Acrivon Therapeutics (ACRV) director receives 20,275 stock options at $1.52 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Acrivon Therapeutics director Palani Santhosh received a stock option grant for 20,275 shares of common stock. The option has an exercise price of $1.52 per share and expires on June 16, 2036. All 20,275 option shares remain held following the grant. The option will vest on the date immediately preceding Acrivon’s next annual meeting of stockholders, conditioned on Santhosh’s continuous service through that vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Palani Santhosh
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 20,275 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 20,275 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 20,275 shares
Exercise price: $1.52 per share
Expiration date: June 16, 2036
+1 more
4 metrics
Options granted
20,275 shares
Stock Option (Right to Buy) grant on June 17, 2026
Exercise price
$1.52 per share
Conversion or exercise price of stock option grant
Expiration date
June 16, 2036
Option expiration for 20,275-share grant
Total options held after grant
20,275 shares
Total derivative shares following transaction
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 1.5200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-16T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders regulatory
"shall vest on the date immediately preceding the date of the Issuer's next annual meeting of stockholders"
continuous service financial
"subject to the Reporting Person's continuous service through the applicable vesting date"
FAQ
What did Acrivon Therapeutics (ACRV) director Palani Santhosh report in this Form 4?
Palani Santhosh reported receiving a stock option grant for 20,275 shares of Acrivon Therapeutics common stock. The filing reflects a compensation-related award, not an open-market purchase or sale, and shows these options as directly held following the transaction.
What is the exercise price and size of the ACRV stock option grant to Palani Santhosh?
The stock option grant covers 20,275 shares of Acrivon Therapeutics common stock with an exercise price of $1.52 per share. This means Santhosh can buy those shares at $1.52 once the options vest, subject to the specified vesting conditions.
When do the stock options granted to ACRV director Palani Santhosh expire?
The stock options granted to Palani Santhosh expire on June 16, 2036. After that date, any unexercised portion of the 20,275-share option grant can no longer be used to purchase Acrivon Therapeutics common stock at the $1.52 exercise price.
What are the vesting conditions for Palani Santhosh’s Acrivon Therapeutics stock options?
The options vest on the date immediately preceding Acrivon Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on Santhosh’s continuous service with the company through that vesting date, so leaving earlier would typically prevent the award from vesting.